Levofloxacin

Generic Name: Levofloxacin

Brand Names: Levaquin, Quinsair

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₀FN_₃O_₄

CAS Number: 100986-85-4

Unique Ingredient Identifier: RIX4E89Y14

Background: Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...

Indication: In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...

Associated Conditions: Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria

Associated Therapies: -

Clinical Trials

An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

Phase 2

Completed

Conditions: Tuberculosis
Multidrug Resistant Tuberculosis
Extensively-drug Resistant Tuberculosis

Interventions: Drug: Pyrazinamide
Drug: Linezolid
Drug: Ethionamide
Drug: Bedaquiline
Drug: Terizidone
Drug: Levofloxacin
Drug: Moxifloxacin
Drug: Kanamycin
Drug: Isoniazid

First Posted Date: 2015-05-27

Last Posted Date: 2021-09-29

Lead Sponsor: University of Cape Town

Target Recruit Count: 154

Registration Number: NCT02454205

Locations: 🇿🇦
Brooklyn Chest Hospital, Cape Town, Western Cape, South Africa

A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control

Phase 3

Completed

Conditions: Acute Lower Urinary Tract Infection

Interventions: Drug: prulifloxacin
Drug: Levofloxacin
Drug: Prulifloxacin Placebo
Drug: Levofloxacin Placebo

First Posted Date: 2015-05-12

Last Posted Date: 2015-07-16

Lead Sponsor: Lee's Pharmaceutical Limited

Target Recruit Count: 216

Registration Number: NCT02439632

Locations: 🇨🇳
Peking Medical Union Hospital, Beijing, China

Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori

Phase 3

Conditions: Helicobacter-associated Gastritis

Interventions: Drug: Metronidazole(MTZ)
Drug: Nitazoxanide
Drug: Omeprazole
Drug: Clarithromycin
Drug: Levofloxacin
Drug: Doxicycline

First Posted Date: 2015-04-21

Last Posted Date: 2017-04-25

Lead Sponsor: Sherief Abd-Elsalam

Target Recruit Count: 120

Registration Number: NCT02422706

Locations: 🇪🇬
Tanta university hospital, Cairo, Egypt

The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

Phase 3

Completed

Conditions: MDR-TB

Interventions: Drug: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)
Drug: Moxifloxacin
Drug: Clofazimine
Drug: Ethambutol
Drug: Pyrazinamide
Drug: Isoniazid
Drug: Prothionamide
Drug: Bedaquiline
Drug: Kanamycin
Drug: Levofloxacin

First Posted Date: 2015-04-06

Last Posted Date: 2023-09-28

Lead Sponsor: IUATLD, Inc

Target Recruit Count: 588

Registration Number: NCT02409290

Locations: 🇪🇹
Armauer Hanssen Research Institute, Addis Ababa, Ethiopia
🇪🇹
St. Peter's Tuberculosis Specializes Hospital, Addis Ababa, Ethiopia
🇬🇪
JSC National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

and more 10 locations

A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP

Phase 3

Completed

Conditions: Community-acquired Pneumonia

Interventions: Drug: Nemonoxacin
Drug: Levofloxacin

First Posted Date: 2014-07-31

Last Posted Date: 2021-10-25

Lead Sponsor: TaiGen Biotechnology Co., Ltd.

Target Recruit Count: 598

Registration Number: NCT02205112

Locations: 🇨🇳
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳
Taipei Medical University - Shuang Ho Hospital, Taipei, Taiwan

and more 60 locations